Cefdinir: Difference between revisions
No edit summary |
Gerald Chi (talk | contribs) |
||
| Line 8: | Line 8: | ||
==Category== | ==Category== | ||
Cephalosporin,Third- | Cephalosporin, Third-Generation | ||
==US Brand Names== | ==US Brand Names== | ||
Revision as of 19:04, 23 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Cefdinir (marketed by Abbott Laboratories under the brand name Omnicef) is a semi-synthetic, broad-spectrum antibiotic in the third generation of the cephalosporin class, proven effective for common bacterial infections of the ear, sinus, throat, and skin. It was approved by the U.S. Food and Drug Administration (FDA) in December of 1997.
Category
Cephalosporin, Third-Generation
US Brand Names
OMNICEF®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings | Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | How Supplied | Labels and Packages
Mechanism of action
Cefdinir is bactericidal except against Listeria monocytogenes where it is bacteriostatic. It inhibits bacterial wall synthesis like other beta-lactam antibiotics. In contrast to other beta-lactams, it is highly resistant to degradation by beta-lactamase or cephalosporinase. Resistance generally arises due to mutations in penicillin binding proteins, production of metallo-beta-lactamases, or resistance to diffusion across the bacterial outer membrane.[1]Unlike imipenem, it is stable to dehydropeptidase-1 and can therefore be given without cilastatin.
References
- ↑ Mosby's Drug Consult 2006 (16 ed ed.). Mosby, Inc. 2006.